Lymphoma begins developing in the lymphocytes, which are cells that fight infections within the immune system. Marginal zone lymphoma (MZL) is a form of non-Hodgkin’s lymphoma that is indolent, or slow growing. MZL consists of 8% of all non-Hodgkin’s lymphoma, so it is not only a rare type of cancer, but a rare subtype of lymphoma. Treatments for Marginal zone lymphoma vary from watchful waiting and active surveillance for early stage patients, to chemotherapy and immunotherapy for advanced stage cases. Early stage treatments hope to contain the tumor and help with the cancer’s symptoms.
For patients looking for other treatment options, clinical trials provide alternative treatments for MZL and other types of lymphoma. Drugs are monitored by the FDA throughout the clinical trial process to ensure its safety for commercial use, then the treatment is approved. Clinical trials can have a strict eligibility criteria, so it is important to find clinical trials specific to your individual case. Artificial intelligence based platforms like the Synergy-AI Clinical Trial Matching System (CTMS) help identify trials out of the hundred’s available for lymphoma to fit your individual MZL case.